PB2102: PHASE 2 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL

Detalles Bibliográficos
Autores principales: Michot, J.-M., Koh, Y., Lee, P., Jin, J., Clynes, R., Kye, S., Chiarella, M., Patel, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431672/
http://dx.doi.org/10.1097/01.HS9.0000851240.74602.7c
_version_ 1784780119302209536
author Michot, J.-M.
Koh, Y.
Lee, P.
Jin, J.
Clynes, R.
Kye, S.
Chiarella, M.
Patel, K.
author_facet Michot, J.-M.
Koh, Y.
Lee, P.
Jin, J.
Clynes, R.
Kye, S.
Chiarella, M.
Patel, K.
author_sort Michot, J.-M.
collection PubMed
description
format Online
Article
Text
id pubmed-9431672
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94316722022-08-31 PB2102: PHASE 2 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL Michot, J.-M. Koh, Y. Lee, P. Jin, J. Clynes, R. Kye, S. Chiarella, M. Patel, K. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431672/ http://dx.doi.org/10.1097/01.HS9.0000851240.74602.7c Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Publication Only
Michot, J.-M.
Koh, Y.
Lee, P.
Jin, J.
Clynes, R.
Kye, S.
Chiarella, M.
Patel, K.
PB2102: PHASE 2 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL
title PB2102: PHASE 2 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL
title_full PB2102: PHASE 2 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL
title_fullStr PB2102: PHASE 2 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL
title_full_unstemmed PB2102: PHASE 2 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL
title_short PB2102: PHASE 2 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL
title_sort pb2102: phase 2 randomized, open-label, multicenter study to evaluate the efficacy and safety of plamotamab combined with tafasitamab (tafa) + lenalidomide (len) vs tafa+len in relapsed or refractory dlbcl
topic Publication Only
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431672/
http://dx.doi.org/10.1097/01.HS9.0000851240.74602.7c
work_keys_str_mv AT michotjm pb2102phase2randomizedopenlabelmulticenterstudytoevaluatetheefficacyandsafetyofplamotamabcombinedwithtafasitamabtafalenalidomidelenvstafaleninrelapsedorrefractorydlbcl
AT kohy pb2102phase2randomizedopenlabelmulticenterstudytoevaluatetheefficacyandsafetyofplamotamabcombinedwithtafasitamabtafalenalidomidelenvstafaleninrelapsedorrefractorydlbcl
AT leep pb2102phase2randomizedopenlabelmulticenterstudytoevaluatetheefficacyandsafetyofplamotamabcombinedwithtafasitamabtafalenalidomidelenvstafaleninrelapsedorrefractorydlbcl
AT jinj pb2102phase2randomizedopenlabelmulticenterstudytoevaluatetheefficacyandsafetyofplamotamabcombinedwithtafasitamabtafalenalidomidelenvstafaleninrelapsedorrefractorydlbcl
AT clynesr pb2102phase2randomizedopenlabelmulticenterstudytoevaluatetheefficacyandsafetyofplamotamabcombinedwithtafasitamabtafalenalidomidelenvstafaleninrelapsedorrefractorydlbcl
AT kyes pb2102phase2randomizedopenlabelmulticenterstudytoevaluatetheefficacyandsafetyofplamotamabcombinedwithtafasitamabtafalenalidomidelenvstafaleninrelapsedorrefractorydlbcl
AT chiarellam pb2102phase2randomizedopenlabelmulticenterstudytoevaluatetheefficacyandsafetyofplamotamabcombinedwithtafasitamabtafalenalidomidelenvstafaleninrelapsedorrefractorydlbcl
AT patelk pb2102phase2randomizedopenlabelmulticenterstudytoevaluatetheefficacyandsafetyofplamotamabcombinedwithtafasitamabtafalenalidomidelenvstafaleninrelapsedorrefractorydlbcl

Ejemplares similares